GlassScriptPhysician profile
Michael J Martin
NPI 1528040623
$7,368.66
in general payments reported to CMS, 2019-2025
45 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $776 · 2021: $900 · 2022: $2,918 · 2023: $1,074 · 2024: $922 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,426.93 | 2019-2024 | |
| Novo Nordisk INC | $1,346.40 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $441.97 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $314.36 | 2021-2025 | |
| Lilly USA, LLC | $269.63 | 2020-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $221.23 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $211.99 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $173.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $161.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.68 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $126.12 | 2023-2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $124.01 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.52 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.58 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $106.55 | 2022-2025 | Eterna, Freestyle Libre 3 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $103.71 | 2019-2024 | Spravato |
| Mannkind Corporation | $92.00 | 2019-2023 | Afrezza |
| Daiichi Sankyo INC. | $87.07 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $72.38 | 2019-2024 | Strensiq |
| Genentech USA, INC. | $68.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.83 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Idorsia Pharmaceuticals US INC | $56.71 | 2023 | Quviviq |
| Insightec,INC | $51.98 | 2023 | Exablate |
| Baxter Healthcare | $49.61 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Biohaven Pharmaceutical Holding Company LTD. | $32.02 | 2022 | |
| Shield Therapeutics INC | $31.40 | 2023-2024 | Accrufer |
| Xeris Pharmaceuticals, INC. | $30.93 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.68 | 2021-2024 | Eliquis |
| Sanofi Pasteur INC. | $27.27 | 2023 | |
| Novavax INC | $26.64 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Currax Pharmaceuticals LLC | $23.24 | 2019-2022 | |
| Eisai INC. | $22.01 | 2024 | |
| Grifols USA, LLC | $19.69 | 2019 | |
| Dynavax Technologies Corporation | $18.65 | 2023 | Heplisav-B |
| Mylan Specialty L.P. | $18.38 | 2020 | |
| Medicure Pharma INC. | $17.47 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.01 | 2021 | |
| Vivus LLC | $15.35 | 2019 | |
| Mdd US Operations, LLC | $15.30 | 2019 | |
| Optinose US, INC. | $14.06 | 2019 | |
| Shire North American Group INC | $13.63 | 2019 | |
| Vyera Pharmaceuticals, LLC | $13.31 | 2021 | |
| Bardy Diagnostics, INC. | $12.00 | 2020 | |
| Allergan, INC. | $11.99 | 2020 | |
| Dermira, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.